# A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma

> **NCT07392866** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Nanjing Sanhome Pharmaceutical, Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** SH006
- **DRUG:** Bevacizumab
- **DRUG:** Oxaliplatin injection
- **DRUG:** Capecitabine
- **DRUG:** Regorafenib

## Key facts

- **NCT ID:** NCT07392866
- **Lead sponsor:** Nanjing Sanhome Pharmaceutical, Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2030-03-01
- **Final completion:** 2030-03-01
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07392866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07392866, "A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07392866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*